Literature DB >> 25796592

Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials.

M E Lynch1, Mark A Ware.   

Abstract

An updated systematic review of randomized controlled trials examining cannabinoids in the treatment of chronic non-cancer pain was conducted according to PRISMA guidelines for systematic reviews reporting on health care outcomes. Eleven trials published since our last review met inclusion criteria. The quality of the trials was excellent. Seven of the trials demonstrated a significant analgesic effect. Several trials also demonstrated improvement in secondary outcomes (e.g., sleep, muscle stiffness and spasticity). Adverse effects most frequently reported such as fatigue and dizziness were mild to moderate in severity and generally well tolerated. This review adds further support that currently available cannabinoids are safe, modestly effective analgesics that provide a reasonable therapeutic option in the management of chronic non-cancer pain.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25796592     DOI： 10.1007/s11481-015-9600-6

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN： 1557-1890            Impact factor:   4.147


  25 in total

1.  An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee.

Authors:  John P Huggins; Trevor S Smart; Stephen Langman; Louise Taylor; Tim Young
Journal:  Pain       Date:  2012-06-21       Impact factor: 6.961

2.  Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis.

Authors:  Niklas Schuelert; Michael P Johnson; Jennifer L Oskins; Karandeep Jassal; Mark G Chambers; Jason J McDougall
Journal:  Pain       Date:  2010-12-24       Impact factor: 6.961

3.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.

Authors:  B F Cravatt; K Demarest; M P Patricelli; M H Bracey; D K Giang; B R Martin; A H Lichtman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

4.  Cannabis use for chronic non-cancer pain: results of a prospective survey.

Authors:  Mark A Ware; Crystal R Doyle; Ryan Woods; Mary E Lynch; Alexander J Clark
Journal:  Pain       Date:  2003-03       Impact factor: 6.961

Review 5.  Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.

Authors:  Mary E Lynch; Fiona Campbell
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

6.  A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain.

Authors:  Mary E Lynch; Paula Cesar-Rittenberg; Andrea G Hohmann
Journal:  J Pain Symptom Manage       Date:  2013-06-04       Impact factor: 3.612

Review 7.  Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations.

Authors:  Meldon Kahan; Anita Srivastava; Sheryl Spithoff; Lisa Bromley
Journal:  Can Fam Physician       Date:  2014-12       Impact factor: 3.275

8.  The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial.

Authors:  Mark A Ware; Mary-Ann Fitzcharles; Lawrence Joseph; Yoram Shir
Journal:  Anesth Analg       Date:  2009-12-10       Impact factor: 5.108

Review 9.  Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Authors:  Roger G Pertwee
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

10.  Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.

Authors:  Jody Corey-Bloom; Tanya Wolfson; Anthony Gamst; Shelia Jin; Thomas D Marcotte; Heather Bentley; Ben Gouaux
Journal:  CMAJ       Date:  2012-05-14       Impact factor: 8.262
View more
  68 in total

1.  Prescribing marijuana for chronic pain.

Authors:  Roger Ladouceur
Journal:  Can Fam Physician       Date:  2015-08       Impact factor: 3.275

2.  Presynaptic and extrasynaptic regulation of posterior nucleus of thalamus.

Authors:  Anthony Park; Ying Li; Radi Masri; Asaf Keller
Journal:  J Neurophysiol       Date:  2017-03-22       Impact factor: 2.714

3.  Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity.

Authors:  Stevie C Britch; Jenny L Wiley; Zhihao Yu; Brian H Clowers; Rebecca M Craft
Journal:  Drug Alcohol Depend       Date:  2017-04-15       Impact factor: 4.492

Review 4.  Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement.

Authors:  Alex Mu; Erica Weinberg; Dwight E Moulin; Hance Clarke
Journal:  Can Fam Physician       Date:  2017-11       Impact factor: 3.275

5.  The Associations of Neighborhood Availability of Marijuana Dispensaries and DATA-2000 Waivered Providers with Hospital Stays Related to Opioids.

Authors:  Di Liang; Yuyan Shi
Journal:  Subst Use Misuse       Date:  2019-08-25       Impact factor: 2.164

Review 6.  Cannabis, Cannabinoids, and Sleep: a Review of the Literature.

Authors:  Kimberly A Babson; James Sottile; Danielle Morabito
Journal:  Curr Psychiatry Rep       Date:  2017-04       Impact factor: 5.285

7.  Antinociceptive effects of JWH015 in female and male rats.

Authors:  Rebecca M Craft; Nicholas Z Greene; Alexa A Wakley
Journal:  Behav Pharmacol       Date:  2018-04       Impact factor: 2.293

Review 8.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

9.  Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ9-Tetrahydrocannabinol and JWH-018.

Authors:  Benjamin M Ford; Christian V Cabanlong; Sherrica Tai; Lirit N Franks; Narsimha R Penthala; Peter A Crooks; Paul L Prather; William E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2019-03-04       Impact factor: 4.030

10.  Preface to DMR special edition 'Cannabinoid receptors and ligands: therapeutic drug development and abuse potential'.

Authors:  Paul L Prather
Journal:  Drug Metab Rev       Date:  2018-01-30       Impact factor: 4.518
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.